220844-82-6

Basic information

• Product Name: 2H-1,4-Benzoxazin-7-amine, 3,4-dihydro-4-methyl-
• CAS NO: 220844-82-6
• Molecular Formula: C9H12N2O
• Molecular Weight: 164.207
• Mol File: 220844-82-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2H-1,4-Benzoxazin-7-amine, 3,4-dihydro-4-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1,4-Benzoxazin-7-amine, 3,4-dihydro-4-methyl-(220844-82-6)
• EPA Substance Registry System: 2H-1,4-Benzoxazin-7-amine, 3,4-dihydro-4-methyl-(220844-82-6)

Safety Data

• Hazardous Substances Data: 220844-82-6(Hazardous Substances Data)

Upstream product

• 120711-93-5 3,4-dihydro-4-methyl-7-nitro-2H-1,4-benzoxazine 
• 81721-86-0 7-nitro-4H-benzo[1,4]oxazin-3-one 
• 5735-53-5 1,4-benzoxazine 
• 120711-81-1 3,4-dihydro-7-nitro-2H-1,4-benzoxazine 
• 141068-81-7 7-amino-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one 

Downstream Products

• 1007197-88-7 C₂₀H₁₇ClN₂O₃ 
• 120711-67-3 3,4-dihydro-7-(2-imidazolin-2-ylamino)-4-methyl-2H-1,4-benzoxazone hydroiodide 

Relevant articles and documents

Guanidine compound for preventing and treating chronic pain medication (by machine translation)

The invention relates to a guanidine compound as shown in general formula (I) as a guanidine compound for preventing and treating chronic pain disease. A pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, a deuterated substanc

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.